oxaliplatin

P=N/A, N=150, Active, not recruiting, Peking University | Not yet recruiting --> Active, not recruiting | Trial completion date: Aug 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Dec 2026

P=N/A, N=96, Recruiting, Tang-Du Hospital | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027

P=N/A, N=550, Recruiting, Assistance Publique - Hôpitaux de Paris | Not yet recruiting --> Recruiting

P2/3, N=900, Recruiting, AbbVie | Not yet recruiting --> Recruiting

P3, N=1083, Recruiting, Maimónides Biomedical Research Institute of Córdoba | Not yet recruiting --> Recruiting

P2, N=60, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027

LP treatment ameliorated these pathological alterations by restoring antioxidant enzyme activities, downregulating proinflammatory and proapoptotic signals, mitigating ER stress and autophagy activation, and reducing PI3K/AKT/mTOR protein expression. These findings demonstrate that LP exerts a renoprotective effect against OXI-induced kidney injury through multi-targeted molecular mechanisms, including modulation of inflammation, oxidative stress, autophagy, apoptosis, and survival signaling pathways.

This study comprehensively identifies the vessel-threatening effects of cisplatin (CDDP), carboplatin (CBP), and oxaliplatin (OXA) and aims to compile an analytical model. The results suggest activation of the oxidative stress pathway through Nrf2 inhibition and increased ICAM1 levels, alongside pathway‑specific alterations such as reduced HIF1A and NOS3 expression and decreased VCAM1 levels. Early cardiovascular monitoring and Nrf2‑targeted therapy warrant further investigation.

This study demonstrates that the GBDT machine learning model effectively predicts OIPN risk in colorectal cancer patients. Combined with SHAP analysis, the model's interpretability is enhanced. The developed online calculator provides a reliable tool for early clinical identification of high-risk patients and personalized intervention strategies.

After neoadjuvant oxaliplatin/capecitabine (CAPOX) therapy, he underwent cystoprostatectomy, urethrectomy, and ileal conduit. Pathology showed stage IIIB disease with negative margins. This case underscores a rare but severe complication of prostate brachytherapy, contributing to the clinical understanding of secondary urethral malignancies.

P2/3, N=272, Not yet recruiting, Unicancer

P2, N=34, Not yet recruiting, Abramson Cancer Center at Penn Medicine | Initiation date: Apr 2026 --> Sep 2026